Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,242 people get SVNT articles and Market Currents by email alert.
Get email alerts on SVNT »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Look Beyond the Botched Buyout Process for Savient's ValueStone Fox Capital • Wed, Oct 27, 2010
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
4 Highly Liquid Biotech Stocks With Bullish Short TrendsKapitall • Thu, May 10, 2012
-
-
AstraZeneca Sprinting To Fix ItselfStephen Simpson • Thu, Apr 26, 2012
-
Savient Pharmaceuticals, Inc Q2 2010 Earnings Call TranscriptWed, Aug 4, 2010
-
Savient Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptSat, May 8, 2010
-
Savient Pharmaceuticals, Inc. Q1 2009 Earnings Call TranscriptFri, May 8, 2009
-
Savient Pharmaceuticals, Inc, Q4 Year Earnings Call TranscriptThu, Feb 26, 2009
-
Savient Pharmaceuticals, Inc. Q4 2007 Earning Call TranscriptWed, Mar 12, 2008
-
Savient Pharmaceuticals Q3 2007 Earnings Call TranscriptWed, Oct 31, 2007
-
PR Newswire (May 15, 2013)
-
PR Newswire (Mar 19, 2013)
-
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.PR Newswire (Feb 19, 2013)
-
PR Newswire (Jan 8, 2013)
-
PR Newswire (Jan 4, 2013)
-
PR Newswire (Dec 5, 2012)
-
PR Newswire (Nov 8, 2012)
-
PR Newswire (Oct 19, 2012)
-
PR Newswire (Sep 26, 2012)
-
at MarketWatch.com (Sep 25, 2012)
-
PR Newswire (Sep 24, 2012)
-
at CNBC.com (Sep 19, 2012)
-
PR Newswire (Sep 5, 2012)
SVNT vs. ETF Alternatives
Company Description
We are a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase), or KRYSTEXXA, for the treatment of chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, June 13, 1:52 PM Savient Pharmaceuticals (SVNT +12.7%) increases the price per vial for Krystexxa to $5,390 for orders effectively placed after 5:00pm EST on May 17. The company adds that it will continue to evaluate pricing, noting that continued substantial price increases will, in light of the current market dynamics, be necessary in the effort to obtain sufficient revenue from the drug. Comment! [Healthcare, On the Move]
- Wednesday, May 15, 7:04 AM Savient Pharmaceuticals (SVNT): Q1 EPS of -$0.34 misses by $0.03. Revenue of $4.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, May 15, 12:05 AM Notable earnings before Wednesday’s open: AG, AH, CSC, DE, EJ, GLOG, M, OXF, PF, SVNT, WMC Comment! [Earnings]
- Tuesday, May 14, 5:30 PM Notable earnings before Wednesday’s open: AG, AH, CSC, DE, EJ, GLOG, M, OXF, PF, SVNT, WMC Comment! [Earnings]
- Tuesday, March 19, 12:00 PM Savient Pharmaceuticals (SVNT -9%) takes a hit after its Q4 beat expectations on a per share basis, but came up far short on revenue as net sales of Krystexxa posted a marginal 3% increase over Q3. Bottom line margins were also impacted by a cost of goods charge to Krystexxa inventory that the company doesn't believe will be sold prior to expiration. 1 Comment [Healthcare, On the Move]
- Tuesday, March 19, 7:04 AM Savient Pharma (SVNT): Q4 EPS of -$0.39 beats by $0.06. Revenue of $4.9M (+33% Y/Y) misses by $1.28M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, March 19, 12:05 AM Notable earnings before Tuesday’s open: DSW, FDS, RNF, SVNT, WAC Comment! [Earnings]
- Monday, March 18, 5:30 PM Notable earnings before Tuesday’s open: DSW, FDS, RNF, SVNT, WAC Comment! [Earnings]
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Thursday, November 8, 2012, 12:45 PM Midday top 10 gainers: DUSA +38%. PRMW +23%. ARX +22%. RST +22%. ES +19%. FALC +18%. UPIP +18%. SAPE +17%. PRSC +17%. MWW +17%. Midday top 10 Losers: CPRX -62%. BCRX -39%. COBR -24%. PRSS -21%. CALI -21%. UPG -20%. SVNT -19%. TRU -19%. MITK -19%. PANL -18%. Comment!
-
Thursday, November 8, 2012, 9:10 AM
Premarket gainers: DUSA +38%. MTSL +28%. USAT +15%. WLL +11%. ITMN +11%. SD +9%. QCOM +9%. THQI +8%. EZCH +7%. ALU +6%. MWW +7%. TTM +6%. DF +5%.
Losers: CPRX -56%. BCRX -34%. PANL -25%. SVNT -19%. SGEN -11%. MNST -10%. CNQR -9%. TNK -9%. NBG -8%. PSTI -8%. MAKO -7%. WINI -6%. AUI -5%. Comment! [On the Move] - Thursday, November 8, 2012, 7:18 AM Savient Pharmaceuticals (SVNT): Q3 EPS of -$0.56 misses by $0.08. Revenue of $4.5M misses by $1.3M. (PR) Comment! [Earnings, Healthcare]
- Thursday, November 8, 2012, 12:05 AM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN Comment! [Earnings]
- Wednesday, November 7, 2012, 5:30 PM Notable earnings before Thursday’s open: AAP, AINV, AMRC, APU, BCRX, CNQ, DF, DUK, EBIX, ES, EZCH, FE, FSYS, GTXI, HK, KIOR, KSS, MFC, MWW, NOG, PGNX, PMT, POZN, PPL, SMBL, SNSS, SVNT, THI, TNK, VMC, WEN, WIN 1 Comment [Earnings]
-
Friday, October 19, 2012, 9:10 AM
Premarket gainers: SVNT +12%. RVBD +11%. CALL +7%. SNDK +7%.
Losers: CBLI -20%. ATHN -11%. CMG -11%. MRVL -9%. PH -9%. ETFC -6%. Comment! [On the Move] - Wednesday, August 8, 2012, 7:43 AM Savient Pharmaceuticals (SVNT): Q2 EPS of -$0.23 beats by $0.22. Revenue of $4.6M (+133% Y/Y) misses by $0.6M. (PR) Comment! [Earnings, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
Cosmospepper
SVNT will be bankrupt, sold or de-listed before Karl Rove is released from the nut house! - View all 0 replies
-
Stone Fox Capital
thx $SVNT management for not even excluding the severance costs in the report. Trying to tank the stock on purpose? - View all 0 replies
-
aeromitch37
Any thoughts on SVNT? I bought at $2.27 and have been murdered since? Should I continue to hold? or sell and take the loss? - View all 0 replies
-
Stone Fox Capital
crazy stuff from $OCZ cutting 28% of non-production workforce. When $SVNT did a similar reduction the stock roared soon after. - View all 3 replies
-
FortSumter: Yeah, imagine the morale there going forward. I've been in that environment and productivity goes to zero as everyone "looks forward". -
Stone Fox Capital: The mega-caps don't b/c the cuts lead to more revenue problems. Small caps though can re-org and focus their way to a turnaround.
-
- View all 0 replies
-
- View all 0 replies
-
Red Acre Investments
$SVNT get EU approval for pegloticase - expect volatile trading as this is last day before op.ex. too - View all 0 replies
-
- View all 2 replies
-
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
-
LATEST REPLIES
-
Stone Fox Capital
crazy stuff from $OCZ cutting 28% of non-production workforce. When $SVNT did a similar reduction the stock roared soon after. - View all 3 replies
-
FortSumter: Yeah, imagine the morale there going forward. I've been in that environment and productivity goes to zero as everyone "looks forward".
-
Stone Fox Capital: The mega-caps don't b/c the cuts lead to more revenue problems. Small caps though can re-org and focus their way to a turnaround.
-
- View all 2 replies
-
Susan Kilburg: SVNT classic setup. Two weeks of consolidation; volume drying up and a bear raid this morning created a perfect buying opportunity.
-
-
- View all 1 replies
-
Susan Kilburg: profit taking and short interest declining as they cover. Absent news, it's the same old same old...
-
- View all 1 replies
-
-
Stone Fox Capital
$SVNT keeps powering ahead to $2.08. Though the 200ema would be a ceiling but it just powered thru... nice - View all 2 replies
-
WildSoccer: Not sure if you're kidding. So if you bought SVNT anytime in the last 15 years except for the last month you're losing money. Nice volume.
-
WildSoccer: Should clarify.SVNT broke through LT downtrend on excell. volume. Next resist. prob.50% higher or so.Nice % upside.Still don't like company.
-
- View all 1 replies
-